Soluble complement receptor type 1 variants and uses thereof

By incorporating at least three C3b binding LHR domains, particularly duplicated LHR-B and/or LHR-C domains, in sCR1 variants, the complement inhibitory activity is enhanced, addressing the translational gap in existing sCR1 therapeutics for treating complement-mediated disorders.

WO2025054666A1PCT designated stage expired Publication Date: 2025-03-20CSL INNOVATION PTY LTD
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
PCT/AU2024/050981
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-09-15
Filing Date
2024-09-13
Publication Date
2025-03-20

Smart Images

  • Figure IMGF000049_0001
    Figure IMGF000049_0001
  • Figure IMGF000050_0001
    Figure IMGF000050_0001
  • Figure IMGF000050_0002
    Figure IMGF000050_0002
Patent Text Reader

Abstract

The present disclosure relates to soluble complement receptor type 1 variants and uses thereof.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • C3b / C4b COMPLEMENT RECEPTOR-LIKE MOLECULES AND USES THEREOF

    WO2002010388A2

  • Soluble complement receptor type 1 variants and uses thereof

    WO2019218009A1

  • Improved vaccinia virus vectors

    WO2023118603A1